# Exportin-1 (XPO1)

Source: https://onco.cc/targets/xpo1/  
OnCo record `xpo1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The export pump that carries tumour suppressor proteins such as p53 out of the nucleus, where they cannot act. Selinexor blocks it so those brakes stay in the nucleus and cancer cells die.

## Summary

Exportin-1, also called CRM1, shuttles more than 200 cargo proteins from the nucleus to the cytoplasm, including p53, p21, FOXO, IkB and the eIF4E-bound oncogene messenger RNAs. Many cancers overexpress it, keeping tumour suppressors out of the nucleus. Selinexor binds covalently to cysteine 528 of XPO1, trapping the suppressors inside the nucleus; it is approved for relapsed multiple myeloma and diffuse large B-cell lymphoma, and is under study in TP53 wild-type endometrial cancer. Nausea, anorexia, weight loss and thrombocytopenia are its main side effects.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Symbol: XPO1
- Class: other
- Biology: Karyopherin that exports nuclear export signal-bearing proteins and some RNAs; inhibited covalently by selinexor at Cys528.
- Where found: Multiple myeloma; Diffuse large B-cell lymphoma; TP53 wild-type endometrial cancer (investigational)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/XPO1
- UniProt O14980: XPO1: https://www.uniprot.org/uniprotkb/O14980/entry

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [Selinexor](https://onco.cc/drugs/selinexor/)
- companies: [Antengene](https://onco.cc/companies/antengene/)

---
JSON: https://onco.cc/api/v1/entities/xpo1.json